World's Best Scientists 2026 revealed!

D-Index & Metrics

Molecular Biology

D-Index
75
Citations
32502
World Ranking
1170
National Ranking
604

Overview

Cyril H. Benes is a researcher affiliated with Harvard University in the United States. Their work spans the fields of Biochemistry, Genetics and Molecular Biology, and Medicine, with a significant focus on Molecular Biology, Oncology, Cancer Research, Computational Theory and Mathematics, and Cell Biology.

Their research investigates multiple aspects of cancer biology and therapeutics, particularly emphasizing cancer genomics and diagnostics, computational drug discovery methods, RNA modifications related to cancer, neuroblastoma research and treatments, cancer hypoxia and metabolism, ubiquitin and proteasome pathways, and mechanisms underlying cancer therapeutics.

Recent published papers by Cyril H. Benes include:

  • Effective drug combinations in breast, colon and pancreatic cancer cells (2022, Nature)
  • Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms (2021, Cancer Cell)
  • MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer (2020, Clinical Cancer Research)
  • Pharmacological blockade of TEAD-YAP reveals its therapeutic limitation in cancer cells (2022, Nature Communications)
  • Therapy-induced APOBEC3A drives evolution of persistent cancer cells (2023, Nature)

Frequent co-authors who have collaborated with Cyril H. Benes include:

  • Patricia Greninger
  • Regina K. Egan
  • Ellen Murchie
  • Mikhail G. Dozmorov
  • Anthony C. Faber

Common venues where Cyril H. Benes has published encompass:

  • Cancer Research
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nature Communications
  • Molecular Cancer Therapeutics
  • Nature

Best Publications

  • Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

    Wanjuan Yang;Jorge Soares;Patricia Greninger;Elena J. Edelman

  • Systematic identification of genomic markers of drug sensitivity in cancer cells

    Mathew J. Garnett;Elena J. Edelman;Sonja J. Heidorn;Christopher Greenman;Christopher Greenman

  • A Landscape of Pharmacogenomic Interactions in Cancer

    Francesco Iorio;Francesco Iorio;Theo A. Knijnenburg;Theo A. Knijnenburg;Daniel J. Vis;Graham R. Bignell

  • Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

    Ryohei Katayama;Alice T. Shaw;Alice T. Shaw;Tahsin M. Khan;Tahsin M. Khan;Mari Mino-Kenudson

  • Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility

    Min Yu;Min Yu;Aditya Bardia;Nicola Aceto;Francesca Bersani

  • Targeting transcription regulation in cancer with a covalent CDK7 inhibitor

    Nicholas Kwiatkowski;Tinghu Zhang;Peter B. Rahl;Brian J Abraham

  • Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

    Alexandre Puissant;Stacey M. Frumm;Gabriela Alexe;Christopher F. Bassil

  • Pharmacogenomic agreement between two cancer cell line data sets

    Nicolas Stransky;Mahmoud Ghandi

  • Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

    Rachel Litman Flynn;Rachel Litman Flynn;Kelli E. Cox;Maya Jeitany;Hiroaki Wakimoto

  • Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer

    Matteo Ligorio;Srinjoy Sil;Jose Malagon-Lopez;Linda T. Nieman

  • Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.

    Ryan B. Corcoran;Katherine A. Cheng;Aaron N. Hata;Anthony C. Faber

  • HER2 expression identifies dynamic functional states within circulating breast cancer cells

    Nicole Vincent Jordan;Aditya Bardia;Ben S. Wittner;Cyril Benes

  • AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

    Sean Caenepeel;Sean P Brown;Brian Belmontes;Gordon Moody

  • ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.

    Stephanie A. Yazinski;Valentine Comaills;Rémi Buisson;Marie Michelle Genois

  • BIM expression in treatment naïve cancers predicts responsiveness to kinase inhibitors

    Anthony C. Faber;Ryan B. Corcoran;Hiromichi Ebi;Lecia V. Sequist

  • TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers

    Anurag Singh;Michael F. Sweeney;Min Yu;Alexa Burger

  • Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase.

    Rémi Buisson;Jessica L. Boisvert;Cyril H. Benes;Lee Zou

  • The C2 domain of PKCdelta is a phosphotyrosine binding domain.

    Cyril H. Benes;Ning Wu;Andrew E.H. Elia;Tejal Dharia

  • TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

    Lipika Goyal;Lei Shi;Leah Y Liu;Ferran Fece de la Cruz

  • Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features

    Rémi Buisson;Rémi Buisson;Adam Langenbucher;Danae Bowen;Eugene E. Kwan

Frequent Co-Authors

Mathew J. Garnett
Mathew J. Garnett Wellcome Sanger Institute
Jeffrey A. Engelman
Jeffrey A. Engelman Novartis Institutes for BioMedical Research (NIBR)
Ultan McDermott
Ultan McDermott AstraZeneca (United Kingdom)
Daniel A. Haber
Daniel A. Haber Harvard University
Olivier Elemento
Olivier Elemento Cornell University
Wafik S. El-Deiry
Wafik S. El-Deiry Brown University
Jeffrey Settleman
Jeffrey Settleman Pfizer (Germany)
Alice T. Shaw
Alice T. Shaw Harvard University
Sridhar Ramaswamy
Sridhar Ramaswamy Harvard University
Lecia V. Sequist
Lecia V. Sequist Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a future in molecular biology, exploring related online degrees can open doors to diverse career pathways. Many students look for flexible learning options that align with their professional goals and lifestyles. For example, programs like capella rn to bsn vs chamberlain rn to bsn highlight how different institutions offer varied curriculum structures and support services, which is important to consider when choosing an online degree.

For those considering an advanced healthcare path, there are accessible online bsn programs available, often featuring accelerated tracks and affordable tuition. Finding a reputable school is critical for a quality education—many students prefer nonprofit online colleges that offer accredited programs with solid student support.

If you’re an active-duty military member or veteran, you might prioritize flexible scheduling and tuition assistance. Several academic institutions offer dedicated resources for service members, and some of the best in the country are recognized as top online military friendly colleges.

Best Scientists Citing Cyril H. Benes

Trending Scientists